GEODE CAPITAL MANAGEMENT, LLC - Y-MABS THERAPEUTICS INC ownership

Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 115 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.

Quarter-by-quarter ownership
GEODE CAPITAL MANAGEMENT, LLC ownership history of Y-MABS THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,874,453
-19.8%
710,833
-0.1%
0.00%
-100.0%
Q2 2023$4,832,198
+45.6%
711,664
+7.4%
0.00%
Q1 2023$3,319,851
+107687.4%
662,645
+5.0%
0.00%
Q4 2022$3,080
-100.0%
631,294
-0.3%
0.00%
-100.0%
Q3 2022$9,126,000
-3.7%
632,895
+1.1%
0.00%0.0%
Q2 2022$9,473,000
+36.7%
626,168
+7.3%
0.00%0.0%
Q1 2022$6,932,000
-31.1%
583,529
-6.0%
0.00%0.0%
Q4 2021$10,066,000
-38.9%
620,977
+7.6%
0.00%
-50.0%
Q3 2021$16,470,000
-11.6%
577,111
+4.7%
0.00%
-33.3%
Q2 2021$18,625,000
+29.9%
551,047
+16.2%
0.00%
+50.0%
Q1 2021$14,337,000
-32.8%
474,118
+10.0%
0.00%
-50.0%
Q4 2020$21,332,000
+38.5%
430,878
+7.4%
0.00%
+33.3%
Q3 2020$15,401,000
-0.6%
401,177
+11.9%
0.00%0.0%
Q2 2020$15,489,000
+93.1%
358,563
+16.7%
0.00%
+50.0%
Q1 2020$8,021,000
-52.9%
307,322
-43.6%
0.00%0.0%
Q4 2019$17,012,000
+219.7%
544,436
+166.6%
0.00%
+100.0%
Q3 2019$5,321,000
+41.0%
204,202
+23.8%
0.00%0.0%
Q2 2019$3,773,000
+60.9%
164,979
+84.4%
0.00%0.0%
Q1 2019$2,345,000
-26.1%
89,470
-42.7%
0.00%
Q4 2018$3,174,000156,0640.00%
Other shareholders
Y-MABS THERAPEUTICS INC shareholders Q4 2020
NameSharesValueWeighting ↓
Memorial Sloan Kettering Cancer Center 191,176$2,271,0002.63%
Sofinnova Investments, Inc. 2,194,278$26,068,0001.98%
MPM BioImpact LLC 443,702$5,271,0001.42%
Soleus Capital Management, L.P. 238,982$2,839,0000.37%
Lombard Odier Asset Management (Switzerland) SA 221,774$2,635,0000.21%
Artal Group S.A. 400,000$4,752,0000.20%
Polar Capital Holdings Plc 2,877,671$34,187,0000.15%
ASHFORD CAPITAL MANAGEMENT INC 106,770$1,268,0000.14%
Cormorant Asset Management, LP 150,000$1,782,0000.14%
Virtus ETF Advisers LLC 23,646$281,0000.13%
View complete list of Y-MABS THERAPEUTICS INC shareholders